MSA Trust

Other MSA and Neurology Research

Listed here are MSA research results and results from other areas of neurology that may be relevant or interesting:

EmeraMed builds momentum in rare disease

EmeraMed’s emeramide saw its PTSR in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) rise by nine points each after a Phase II trial was completed. The PTSR in PSP currently sits at 27% while that in MSA is now 56%. PSP and MSA are both atypical forms of Parkinson’s disease.

The Phase II placebo-controlled crossover study (NCT04184063) evaluating the drug’s effect on symptoms and health-related quality of life over 28 days enrolled 20 patients with PSP or MSA. Emermaide, also known as NBMI, is an oral isophthalamide derivative that can prevent oxidative damage and reduce disease toxicity.

The study completion, which was posted to on 23 September, resulted in a modest one-point bump to the drug’s LoA in MSA to 2%, but there was no LoA change in PSP, which remained at 1%. EmeraMed is headquartered in Ireland and also operates in the US and Sweden.

Read more about the trial on the website


Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 (

See the conference poster here



Results of M-Star trial announced. We have been disappointed to learn from Biohaven that one of the possible treatment drugs, Verdiperstat, for MSA has not given the results hoped for in the phase three trial undertaken over the past year. Our Biohaven colleagues have said ‘Thank you so much for all your incredible effort and hard work on this trial. We could not have done this without your support – from helping with recruitment to connecting us with people with MSA and their families to understand their experience better. We are hoping that this global MSA study (the largest ever conducted) will help further the research for this rare degenerative disease. ‘ Read the full press release here.

Biohaven have provided answers to the follow questions for us to share –

Will the open-label extension program continue?

Yes. All patients who completed the double-blind phase of the M-STAR trial and are currently on the Open Label Extension will be able to stay on verdiperstat for the full 48 weeks, if they wish to continue.

What should I do next?

We encourage people currently on the M-STAR study to consult their study physician and site to discuss the next steps in their treatment plan. Their study physician should be reaching out to them soon.



Here is a podcast by Dr Camille Carroll Associate Professor and Honorary Consultant Neurologist Peninsula Medical School (Faculty of Health), NSL for Neurology NIHR CRN, talking about The role of digital, technology, such as sensors and wearables, in clinical trials

Research project ‘Abdominal Binders to Treat Orthostatic Hypotension in Multiple System Atrophy’ receives additional funding

Alterity Therapeutics press release announces publication of data for ATH434 (a small molecule drug candidate) in a mouse model of Multiple System Atrophy

The full publication ‘ATH434 Reduces a-Synuclein-Related Neurodegeneration in a Murine Model of Multiple System Atrophy’ on the Movement Disorders Journal website

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Researchers move closer to a test that can sniff out Parkinson’s

Creating drugs to restore mitochondria and stop Parkinson’s

Parkinson’s results beyond researchers’ wildest dreams

The MSA Coalition (USA) research news and therapeutic pipeline summary